Sign In
Buy CELZ
$0.86
-0.0160 (-1.82%)
At Close: Jul 20, 2026
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
09:15am, Tuesday, 07'th Oct 2025
Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical's Similar Research Focus Recent Issuance
New Strong Sell Stocks for July 31st
06:46am, Thursday, 31'st Jul 2025
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 25'th Mar 2025
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in t
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year?
10:40am, Tuesday, 25'th Mar 2025
Here is how Creative Medical Technology Holdings, Inc. (CELZ) and 89BIO (ETNB) have performed compared to their sector so far this year.
Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds
08:10am, Thursday, 06'th Mar 2025
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a leading biotechnology innovator in regenerative medicine, today announced
PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a pioneering biotechnology firm specializing in r
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
09:25am, Tuesday, 11'th Feb 2025
Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201 Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
08:25am, Wednesday, 05'th Feb 2025
PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine so
PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative medicine, today announced promising
PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology leader in regenerative medicine, is pleased to announce the successful completion
PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology
Creative Medical Technology Holdings Provides Corporate Update
08:30am, Wednesday, 10'th Jul 2024
PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a rege
